HCV Forecast: Merck, AbbVie Next-Gen Data Not Overtaking Gilead
Executive Summary
Gilead's ASTRAL study data at AASLD represent a "shock-and-awe" campaign, setting up the company for continued HCV dominance over several competitors, Wall Street analyst asserts.
You may also be interested in...
December Approvals Forecast: FDA Decisions Will Be Fast And Frequent
Another record-breaking year of approvals seems almost certain given the number of products with user fee goals before the end of 2015.
Decompensated Cirrhosis May Be Another HCV Edge For Gilead; Bristol, J&J Still In Contention
Bristol and Johnson & Johnson have not abandoned their efforts to take a relevant place in the HCV market, although J&J isn't expected to produce triple combination data until next year.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.